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Background: PAX8 is a member of the paired box (Pax) multigene family of transcription factors, which are involved in
the developmental and tissue-specific control of the expression of several genes in both vertebrates and invertebrates.
Previously, several studies reported that PAX8 is expressed at high levels in specific types of tumors. In particular, PAX8
has been recently reported to be conspicuously expressed in human ovarian cancer, but the functional role of PAX8 in
the carcinogenesis of this type of tumor has not been addressed. In this study, we investigated the contribution of PAX8
in ovarian cancer progression.
Methods: Stable PAX8 depleted ovarian cancer cells were generated using short hairpin RNA (shRNA) constructs. PAX8
mRNA and protein were detected by RT-PCR, immunoblot and immunofluorescence. Cell proliferation, motility
and invasion potential of PAX8 silenced cells were analyzed by means of growth curves, wound healing and Matrigel
assays. In addition, PAX8 knockdown and control cells were injected into nude mice for xenograft tumorigenicity
assays. Finally, qPCR was used to detect the expression levels of EMT markers in PAX8-overexpressing and control cells.
Results: Here, we show that PAX8 plays a critical role in the migration, invasion and tumorigenic ability of ovarian
cancer cells. Our results show that RNA interference-mediated knockdown of PAX8 expression in SKOV-3 ovarian
cancer cells produces a significant reduction of cell proliferation, migration ability and invasion activity compared
with control parental SKOV-3 cells. Moreover, PAX8 silencing strongly suppresses anchorage-independent growth
in vitro. Notably, tumorigenesis in vivo in a nude mouse xenograft model is also significantly inhibited.
Conclusions: Overall, our results indicate that PAX8 plays an important role in the tumorigenic phenotype of
ovarian cancer cells and identifies PAX8 as a potential new target for the treatment of ovarian cancer.
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Ovarian cancer accounts for approximately 3% of all
cancers in women and has the highest mortality of all
cancers of the female reproductive system. This reflects,
in part, a lack of early symptoms and proven ovarian
cancer screening tests. Malignant surface epithelial tumors
(carcinomas) are the most common ovarian cancers,
accounting for 90% of cases. These tumors differentiate
during malignant transformation into four major histo-
types: serous, mucinous, endometrioid and clear cell. The
overall picture suggests that ovarian cancer, like other
cancers, is a spectrum of diseases and not a single disease
entity [1]. Recently, gene expression profiling studies have* Correspondence: s.zannini@ieos.cnr.it
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reproduction in any medium, provided the orindicated that the transcription factor PAX8 is a potential
diagnostic marker for ovarian carcinoma [2].
PAX8 is a member of the PAX gene family, consisting
of nine well-described transcription factors (PAX1-9). The
temporal and spatial expression patterns of PAX genes are
tightly regulated, and their expression is observed primar-
ily during fetal development [3]. In most cases, PAX gene
expression attenuates when development is complete, but
in a few tissues, it persists into adult life. However, abnor-
mal cell growth and proliferation is often associated with
high expression levels of PAX genes [4]. Nevertheless, the
precise role that PAX genes play in cancer is still unclear.
Cancer-promoting PAX genes might not themselves be
responsible for cells shifting to a tumorigenic state, but
following tumor onset, PAX genes clearly play important
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iginal work is properly credited.
Di Palma et al. BMC Cancer 2014, 14:292 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/292malignancy. In fact, overexpression of PAX proteins per se
does not appear to be an initiating or transforming
molecular event in tumor pathogenesis, but it facili-
tates malignant development through the effects of
PAX genes on apoptosis resistance, tumor cell prolifer-
ation and migration, and repression of terminal differ-
entiation [4].
PAX8 plays a key role in thyrocyte differentiation [5].
It is expressed during the organogenesis of the thyroid
gland, Mullerian tract, and kidney, as well as in the adult
thyroid and kidney [6]. Knockout mice lacking PAX8
have a smaller thyroid, with normal calcitonin-producing
parafollicular C cells but no follicular cells; thus, they
suffer from severe hypothyroidism [7]. Congenital hypo-
thyroidism is caused by several genetic defects, and
among these there are mutations of the PAX8 gene [8].
In addition to hypothyroidism, PAX8 plays a role in the
progression of follicular thyroid carcinomas and aden-
omas [9] and is overexpressed in the majority of gliomas,
Wilms tumors and well-differentiated pancreatic neuroen-
docrine tumors [10-12]. Interestingly, aberrant expression
of PAX8 has been reported in epithelial ovarian cancer
[13], and it was described as one of the top 40 genes
specifically upregulated in different types of ovarian
carcinomas [14]. PAX8 is not expressed in the surface
epithelial cells of the ovary; however, recently its expres-
sion was found in 96% of serous ovarian carcinomas, in
89% of endometrioid and 100% of clear cell carcinomas,
whilst was not detected in mucinous carcinomas [9].
Recently, it has been demonstrated that high-grade
serous carcinoma (HGSC) originates in fallopian tubal
secretory epithelial cells, which are positive for PAX8
expression [15].
Our studies provide strong evidence that PAX8 plays
an important role in the tumorigenicity of ovarian cancer
cells both in vitro and in vivo and identify PAX8 as a
major biomarker and target for ovarian cancer.
Methods
Cell culture and DNA transfection
The human ovarian carcinoma cell lines SKOV-3, TOV-
21G, OVCAR-3, TOV-112D and A2780 were obtained
from the CEINGE Cell Culture Facility (Naples, Italy) and
were grown in RPMI medium (Euroclone) containing 10%
fetal bovine serum (Euroclone). The medullary and cor-
tical cells were kindly provided by Prof. Lucio Nitsch
(University of Naples, Italy) and were maintained in
CHANG MEDIUM C lyophilized kit (Irvine Scientific).
The nontumorigenic ovarian cells IOSE-80PC were ob-
tained by Canadian Ovarian Tissue Bank and were grown
in medium 199:MCDB 105 (Sigma-Aldrich) containing
10% fetal bovine serum. For stable transfection experi-
ments, cells were plated at 5 × 105 cells/100-mm tissue
culture dish 24 h prior to transfection. Transfections werecarried out with the Lipofectamine (Invitrogen) and
FUGENE reagent (Promega) for SKOV-3 and IOSE-80PC
cells, respectively, according to the manufacturer's direc-
tions. Forty-eight hours later, transfected cells SKOV-3
and IOSE-80PC were selected in the presence of 0.4 μg/ml
of puromycin (Sigma-Aldrich) and 0.2 mg/ml of G418
(Gibco), respectively.
RNA extraction, RT-PCR analysis and quantitative real
time RT–PCR
Total RNA was extracted using TRIzol reagent (Invitrogen)
and cDNA was synthesized using iScript cDNA Synthesis
kit according to the manufacturer’s instructions (Biorad).
Subsequently, cDNA was used for each PCR reaction with
each primer pair. The PAX8 specific primers designed to
detect PAX8 splice variants were previously described [13].
Real time RT–PCR analysis was performed using IQ™ SYBR
Green PCR Master Mix (Biorad) in a iCycler IQ™ real-time
detection system (Biorad).
Cell extracts and Western blot
Cell extracts and western blot were carried out as previ-
ously described [16].
shRNA, plasmid and antibodies
Five shRNA targeting PAX8, Mission shRNA lentiviral
plasmids (SHCLNG-NM_003466, Sigma-Aldrich) and
MISSION Non-targeting shRNA control vector (SHC002,
Sigma-Aldrich) were used. The 3XFLAG-Pax8 expression
vector was previously described [16]. The antibodies used
for immunofluorescence and immunoblotting were: Pax8
(kindly provided by Prof. R. Di Lauro), fibronectin clone
IST4 (Sigma-Aldrich), vimentin, twist, vinculin, actin and
α-tubulin (Santa Cruz Biotechnology).
Cell proliferation and invasion assay
To evaluate cell growth, SKOV-3, SKOVCtrl-, siCl32,
and siCl48 cells were plated at 8 × 104 cells per 60-mm
plate. The medium was changed every 24 h, and every
24 h cells were collected and counted. Cell invasion assay
was examined using a reconstituted extracellular matrix
(Matrigel; BD Biosciences). Filters (8 μm pore size) on the
bottoms of the upper compartment of the transwells
(6,5 mm; Corning) were coated with 2 mg/ml of matrigel.
2 × 105 cells were suspended in 100 μl of RPMI with 0.2%
FBS. The cells were then plated onto the coated wells and
incubated at 37°C for 16 h. Medium in the lower compart-
ment was supplemented with 5% FBS as a chemoattract-
ant. Noninvading cells were removed from the top of the
wells with a moistened cotton swab. Cells that penetrated
the membrane were fixed with 11% glutaraldehyde and
stained with 0.1% crystal violet. The concentration of solu-
bilized crystal violet in 10% acetic acid was evaluated as
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ent experiments.
Immunofluorescence and Confocal Laser Scanning
Microscopy
Cells were grown directly on glass coverslips for 48-72 h,
fixed in 4% paraformaldehyde in PBS for 20 min at room
temperature, permeabilized for 10 min in 0.2% Triton X-
100 in PBS, and incubated for 60 min in 0.5% BSA (bovine
serum albumin) in PBS. The coverslips were subsequently
incubated at 4°C for 1 h with rabbit polyclonal anti-PAX8
diluted 1:1000 in 0.5% BSA in PBS and, after PBS washing,
incubated for 30 min with Alexa Fluor-594 goat anti-
rabbit IgG (Vinci Biochem) diluted 1:200 in 0.5% BSA in
PBS. After final washings with PBS, the coverslips were
mounted on a microscope slide using a 50% solution of
glycerol in PBS. Images were collected with a Zeiss LSM
510 confocal laser scanning microscope, equipped with a
543 nm HeNe laser, and a Plan-Apochromat 63/1.4 oil
immersion objective. Emitted fluorescence was detected
using LP 560 long pass filter for TRITC.
Wound-healing assay
Confluent SKOVCtrl-, siCl32, and siCl48 cells plated on
tissue culture dishes were wounded by manual scratching
with 200-μl pipette tip, washed with PBS and incubated
at 37°C in complete media. At the indicated time
points, phase contrast images at specific wound sites
were captured.
Anchorage-independent growth in soft agar
Cells were mixed in RPMI 2X (Sigma-Aldrich Aldrich),
tryptose phosphate buffer, and 1.25% of Noble Agar
(Difco Laboratories Inc.) and plated in 60-mm dishes on
the top of 1% agar base. The colonies were allowed to
grow in incubator at 37°C, 5% CO2 for 2 to 3 weeks.
The images of cell colonies were captured with an
inverted microscope.
Animal experiments
All animal studies were conducted at Biogem Scarl Ariano
Irpino, AV (Italy), Preclinical Research and Development
Service. Nude female NOD-SCID mice (NOD-CB17/
PRKDC/J) were purchased from Charles River Laborator-
ies International, Wilmington, MA. Animals have been
housed and used following the rules of the Italian laws
(DL.vo N° 116 - 27/01/1992 and related) and of the EU
directive (2010/63/UE - 22/09/2010) on the protection of
animals used for experimental purposes. All the in vivo
procedures were in compliance with the Guide for the
Care and Use of Laboratory Animals (United States
National Research Council, 1996). All the in vivo ex-
perimental activities were evaluated and approved by
the Committee for the Ethics of the Experimentationson Animals (CESA) of Biogem (ID code 4215) and were
authorized by the Italian Minister of Health.
To generate xenografts, human ovarian cancer cells
were cultured in DMEM with 10% heat-inactivated
FBS. 24 six-week-old nude female NOD-SCID mice (NOD-
CB17/PRKDC/J) (Charles River Laboratories International)
were randomly assigned to four groups: the SKOV3 group
(n = 6), SKOV3Ctrl- group (n = 6), siCl32 group (n = 6) and
siCl48 group (n = 6). They were injected subcutaneously in
the both flanks with 7×106 cells suspended in 0.2 ml PBS/
Matrigel Matrix GF (1:1) (BD Biosciences). Mice were daily
monitored for clinical signs and mortality. Body weight re-
cordings were carried out weekly. Tumor growth was
measured twice a week with a Mitutoyo caliper. The for-
mula TV (mm3) = [length (mm) × width (mm)2]/2 was
used. At the end of the study mice were sacrificed by cer-
vical dislocation.
Results
PAX8 expression in human ovarian cancer cell lines
It has been recently reported that PAX8 is expressed in
a subset of epithelial tumors [17] and could be a useful
marker for the detection and differential diagnosis of
ovarian carcinoma [9]. We first examined the expression
of PAX8 in several ovarian cancer cell lines by RT-PCR and
immunoblotting (Figure 1A). PAX8 is expressed at high
levels in SKOV-3, TOV-21G and OVCAR-3 ovarian cancer
cell lines, whereas it is undetectable in two primary normal
ovarian cultures (medullary and cortical cells) and in the
TOV-112D and A2780 ovarian cancer cell lines. The mul-
tiple bands detected by RT-PCR and Western blot corres-
pond to different PAX8 isoforms previously described [18].
Furthermore, the subcellular localization of PAX8 protein
was analyzed by immunofluorescence and specific staining
was observed exclusively in nuclei, as expected (Figure 1B).
To investigate the role of PAX8 in the tumorigenic
properties of ovarian cancer cells, we silenced PAX8 ex-
pression in the SKOV-3 cell line using shRNA plasmid
vectors. Specifically, we stably transfected the cells with
a pool of five plasmid vectors, each containing an
shRNA targeting a different region of PAX8 cDNA. This
strategy enabled us to achieve >70% inhibition of PAX8.
Figure 1C shows, by means of indirect immunofluorescence
and Western blot with a specific anti-PAX8 antibody, the
inhibition of PAX8 expression in two independent repre-
sentative clones (siCl32 and siCl48), compared to cells
transfected with the control vector containing a scrambled
shRNA (SKOVCtrl-).
shRNA-mediated PAX8 knockdown in SKOV-3 cells leads to
reduced cell proliferation and suppresses cell migration
and invasion
To examine whether high levels of PAX8 could directly
contribute to the tumorigenicity of ovarian cancer cells,
Figure 1 Expression of PAX8 in ovarian cancer cell lines. (A) RT-PCR was performed using total RNA from the indicated cell lines. β-actin
mRNA was amplified as control. Total protein extracts prepared from the same cell lines were separated on SDS-PAGE and subjected to Western
blot analysis with a specific anti-PAX8 antibody. The hybridization with actin assessed the protein uniform loading and integrity. PAX8 splice
variants are indicated in both experiments. (B, C) ovarian cells were grown directly on glass coverslips and stained for indirect immunofluorescence
with the anti-PAX8 antibody. The fluorescence signals were acquired at a confocal microscope, by line-wise scanning. In panel B cells are:
a, medullary cells; b, cortical cells; c, SKOV-3; d, TOV-21G; e, TOV-112D; f, A2780 cells. In panel C, the extent of Pax8 silencing measured by
Western blot is shown.
Di Palma et al. BMC Cancer 2014, 14:292 Page 4 of 8
http://www.biomedcentral.com/1471-2407/14/292we analyzed whether PAX8 silencing was able to modify
the oncogenic properties of SKOV-3 cells. Indeed, growth
curve experiments clearly demonstrate that PAX8 ex-
pression confers a proliferative advantage to SKOV-3 cells
(Figure 2A).
To further study the role of PAX8 in cell migration and
invasion, wound healing and transwell assays were per-
formed. In the wound healing assays, we compared the
cell mobility of the siCl32 and siCl48 independent stable
clones with that of SKOVCtrl- cells. After 8 hours, the area
of the wound was significantly re-covered by migrating
SKOVCtrl- cells, and after 24 hours the wound area had
been completely re-covered (Figure 2B). These cells be-
haved exactly like SKOV-3 parental cells in all analyses
(data not shown). In contrast, the motility of the two
siPAX8 clones was significantly decreased and correlated
with PAX8 expression levels. Indeed, wound closure of thesiCl48 clone (that expresses very low levels of PAX8, see
Figure 1C) was not significant after 8 hours and was only
partial after 24 hours (Figure 2B), suggesting that PAX8 si-
lencing strongly reduces the migration ability of SKOV-3
ovarian cancer cells. Next, the ability to invade Matrigel
was assessed using a Transwell assay (Figure 2C). The inva-
siveness of PAX8 silenced cells was decreased. In particular,
the invasion ability of siCl48 cells was reduced ~8-fold
compared to control cells (Figure 2C). All together, these
results indicate that PAX8 is involved in cell migration and
invasion capabilities of ovarian cancer cells.
PAX8 is important for anchorage-independent growth
and in vivo tumorigenesis
To investigate the importance of PAX8 in the tumorigen-
icity of ovarian cancer cells in vitro and in vivo, we per-
formed soft agar and nude mice assays. SKOVCtrl- cells
Figure 2 PAX8 silencing in SKOV-3 cells inhibits cell proliferation, migration, and invasion. (A) growth curves of SKOV-3,
SKOVCtrl-, siCl32, and siCl48 cells are shown. Triplicate of 8 × 104 cells were seeded into 60-mm plate. Cell numbers were counted on
days 1, 2, 3, 4, 5 and 6 after seeding. (B) wound-healing migration assay for SKOVCtrl-, siCl32, and siCl48 were performed. The healing
of the wounds by migrating cells was imaged at time 0, 8 and 24 h (upper panel). Quantitation of the wound-healing migration assay.
Wound closure was calculated as the distance covered by cells in relation to the initial wound diameter, as determined at 0 h. Wound
closure is expressed as the percentage of the initial wound diameter at 0 h. Data are expressed as the mean ± SD (Ρ < 0.01, bottom
panel). (C) Matrigel invasion assay of SKOVCtrl-, and siPAX8 clones is shown. Columns, mean of three independent experiments; bars,
SD (Ρ < 0.05).
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whereas siPAX8 cells exhibited a significant reduction in
anchorage-independent growth on soft agar; only small
aggregations of cell debris were observed (Figure 3A).
These results unambiguously suggest that PAX8 is essen-
tial for anchorage-independent growth of SKOV-3 cells.
Subsequently, to examine the contribution of PAX8 to
in vivo tumorigenesis, SKOVCtrl-, siCl32, siCl48 and
parental cells were separately injected into the flanks of
nude mice and the growth of the tumors was monitored.
As shown in Figure 3B, SKOV-3 parental cells formed
tumors with the same efficiency as the SKOVCtrl- cells.
While siCl32 and siCl48 cells were able to form tumors,
the tumors were much smaller, and their size correlated
with PAX8 expression levels (Figure 3B). At the end of
the experiment, all the tumors were excised and the
quantitative analysis is shown in Figure 3C. These data
emphasize that PAX8 overexpression is crucial for in vivo
tumorigenesis.PAX8 induces EMT in normal ovarian cells
Having previously established that PAX8 enhances motil-
ity, invasion and tumor formation, we hypothesized that it
could also play a role in epithelial-mesenchymal transition
(EMT). To test this hypothesis, we stably transfected the
IOSE-80PC normal ovarian cell line with full-length PAX8
and isolated several independent clones. By Q-PCR and
Western blot, we analyzed the expression levels of epi-
thelial and mesenchymal markers in two representative
clones (IOSE80-3XFP8-IB9 and IOSE80-3XFP8-IIIB5).
Although E-cadherin expression could not be detected in
these cells, several genes that act as E-cadherin repressors,
such as Snail, Twist and Zeb2 [19] were significantly
upregulated in PAX8 overexpressing IOSE-80PC stable
clones compared to control mock transfected cells
(Figure 4A and B). At the same time, the expression
levels of some mesenchymal markers like fibronectin
and vimentin were significantly increased (Figure 4A
and B). In addition, we measured the expression levels
Figure 3 Loss of PAX8 inhibits anchorage-independent growth in soft agar and suppresses tumorigenesis in nude mice. (A) soft agar
growth of SKOVCtrl-, and siPAX8 cells was assessed and photographed. Columns, mean of three independent experiments; bars, SD (Ρ < 0.05).
(B) growth curves of tumors in tumor-bearing nude mice injected with SKOV3, SKOVCtrl-, siCl32 and siCl48 cells. Data are plotted as the mean
volume ± SD (n = 6 for each group). (C) representative images of SKOV3, SKOVCtrl-, siCl32 and siCl48 tumors following surgical resection.
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overexpressing IOSE-80PC cells (Figure 4A), in agreement
with recent data indicating that TIMP3 is negatively regu-
lated by SNAIL [20]. The metalloproteinases MMP2 and
MMP9 are also regulated by SNAIL [20]; however, in our
cells, no significant changes in the expression of these
metalloproteinases were observed (data not shown). At
the same time, the expression level of MMP13 was signifi-
cantly upregulated suggesting that in different contexts,
other metalloproteinases could be regulated by SNAIL.
Discussion and Conclusions
Epithelial Ovarian Cancer (EOC) is a morphologically
and biologically heterogeneous disease and remains a
leading cause of morbidity and mortality. It accounts for
approximately 3% of all cancers in women and despite
considerable efforts to improve early detection and ad-
vances in chemotherapy, the highest mortality rate of
ovarian cancers has markedly increased worldwide.
There is ample evidence that dysregulated expression
and/or activation of specific members of the PAX family
appear to play a major role in the progression of specific
cancers arising in those organ systems in which PAX
proteins exert their developmental functions duringembryogenesis [21], but their precise role in cancer is
still unclear. Recently, a genome-scale analysis of 102
cancer cell lines identified PAX8 as a lineage-specific
survival gene, highly expressed in ovarian cancer lines
and amplified in a substantial fraction of primary ovarian
tumors [22]. It was initially hypothesized that epithelial
ovarian cancer derives from the epithelial cells covering
the ovary, but recent evidences showed that high-grade
serous carcinoma (HGSC) originates in the fallopian tubal
secretory epithelial cells, which are positive for PAX8 ex-
pression [15]. Newly, we have demonstrated that PAX8
plays a critical role in cell cycle progression and cell
survival of differentiated epithelial cells [23], reinforcing
the crucial involvement of this transcription factor in
different biological processes. To investigate the role of
PAX8 in ovarian cancer we performed studies in vitro and
in vivo. We analyzed the expression level of PAX8 in a
series of ovarian cancer cell lines, thus we have chosen
SKOV-3 cell lines to assess PAX8 involvement in ovarian
tumorigenesis. We selected stable cell clones constitu-
tively silenced by sh-PAX8 to detect the function of this
transcription factor in an epithelial ovarian cancer cell
line. Our results indicated that PAX8 knock-down elicited
a dramatic effect on SKOV-3 cell growth, inhibited the
Figure 4 Expression of PAX8 induces EMT in normal ovarian cells. (A) Quantitative PCR for Snail, Zeb2, Twist, Fibronectin, Vimentin, MMP13
and TIMP3 in IOSE80-3XFP8-IB9 and IOSE80-3XFP8-IIB5 clones (IOSE-80PC cells transfected with 3XFLAG-Pax8) and in IOSE80-Ctrl (IOSE-80PC
transfected with the backbone vector). Columns, mean of three independent experiments in duplicate; bars, SD. *, Ρ < 0.01. (B) Total protein extracts of
IOSE80-Ctrl cells and independent stable clones IOSE80-3XFP8-IB9 and IOSE80-3XFP8-IIB5 were separated on SDS-PAGE and subjected to Western blot
analysis with specific antibodies as indicated in the panel. The hybridization with vinculin assessed the protein uniform loading and integrity.
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reduced the migration rate in wound-healing assay. To
assess the ability of PAX8 to inhibit tumor growth in vivo,
we injected SKOV-3 cells constitutively silenced by
shPAX8 into nude mice. The results obtained in this study
show for the first time that PAX8 is capable of inducing
in vivo tumor growth. The size of palpable lesions well
correlates with PAX8 expression level of single clones,
confirming the role of PAX8 as oncogene in vivo.
Recently, consistent with our findings, it was reported
that PAX8 transcriptionally regulates E2F1, a key regulator
of the G1/S phase of the cell cycle [24]. To date, the essen-
tial role of PAX8 in the development and differentiation ofthe thyroid gland has been extensively described; nonethe-
less, its role in other contexts has not been addressed. Our
data provide the first evidence of a clear involvement of
PAX8 in the in vivo tumorigenesis of ovarian cancer cells.
Given the enormous heterogeneity of ovarian cancer and
the enhanced expression of PAX8 only in some epithelial
subtypes, it will be very interesting to see if a subset of
novel PAX8 target genes is relevant for cancer initiation
and/or maintenance, in order to identify novel targets for
ovarian cancer therapy.
To further characterize PAX8 effects on cell migration
and invasion we analyzed the expression level of some
master regulators of EMT [19] in normal ovarian cell
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reported that the expression of PAX8 significantly induces
SNAIL and MMP13 while inhibits TIMP3, reinforcing the
idea that this transcription factor might represent a poten-
tial new target for preventing ovarian tumor invasion and
metastasis. In conclusion, we believe that the role of PAX8
in cancer is emerging as an exciting research area and
promises to deliver many new insights into the onset and
growth of ovarian epithelial carcinomas.
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